Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1

Telomir Pharmaceuticals (TELO) announced results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species. Telomir’s lead compound, Telomir-1, was developed to neutralize metal-induced oxidative stress-a key driver of AMD progression. In a recently conducted preclinical study using human retinal cell lines, Telomir-1 demonstrated the ability to significantly reduce ROS levels, thereby reversing oxidative damage, suggesting therapeutic potential in AMD and other retinal diseases. Key Study Findings: Copper and iron exposure significantly increased ROS levels in human retinal cells, accelerating oxidative stress and cellular damage. Telomir-1 treatment resulted in a significant reduction of copper and iron-induced ROS elevation, mitigating oxidative stress at the cellular level. Telomir-1 exhibited strong ROS reduction properties at low concentrations, suggesting regulatory, rather than chelation properties, and a high therapeutic potential for AMD. The ability to reduce oxidative stress may have implications beyond AMD, potentially benefiting other retinal diseases linked to oxidative damage. Telomir has planned AMD disease models to further evaluate the efficacy of Telomir-1 in vivo. These studies will explore how Telomir-1 can protect against progressive retinal degeneration and vision loss, paving the way for potential clinical development. In addition to AMD, Telomir will be conducting studies to evaluate the potential of Telomir-1 in Wilson’s disease, progeria, cancer, Alzheimer’s, and other age-related conditions. Furthermore, research will be expanded into infectious diseases, including influenza and bird flu, to assess how Telomir-1’s metal ion regulation capabilities may impact viral pathogenesis and immune response.